- Home
- PSNL vs BOLD Comparison
PSNL vs BOLD Comparison
Compare PSNL & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PSNL
- BOLD
- Stock Information
- Founded
- PSNL 2011
- BOLD 2018
- Country
- PSNL United States
- BOLD United States
- Employees
- PSNL N/A
- BOLD N/A
- Industry
- PSNL Medical Specialities
- BOLD
- Sector
- PSNL Health Care
- BOLD
- Exchange
- PSNL Nasdaq
- BOLD Nasdaq
- Market Cap
- PSNL 321.1M
- BOLD 81.0M
- IPO Year
- PSNL 2019
- BOLD 2024
- Fundamental
- Price
- PSNL $5.19
- BOLD $2.95
- Analyst Decision
- PSNL Strong Buy
- BOLD Strong Buy
- Analyst Count
- PSNL 4
- BOLD 3
- Target Price
- PSNL $6.81
- BOLD $23.00
- AVG Volume (30 Days)
- PSNL 439.4K
- BOLD 57.8K
- Earning Date
- PSNL 11-06-2024
- BOLD 11-11-2024
- Dividend Yield
- PSNL N/A
- BOLD N/A
- EPS Growth
- PSNL N/A
- BOLD N/A
- EPS
- PSNL N/A
- BOLD N/A
- Revenue
- PSNL $80,027,000.00
- BOLD N/A
- Revenue This Year
- PSNL $10.85
- BOLD N/A
- Revenue Next Year
- PSNL $8.77
- BOLD N/A
- P/E Ratio
- PSNL N/A
- BOLD N/A
- Revenue Growth
- PSNL 19.20
- BOLD N/A
- 52 Week Low
- PSNL $0.89
- BOLD $2.82
- 52 Week High
- PSNL $7.20
- BOLD $15.24
- Technical
- Relative Strength Index (RSI)
- PSNL 56.29
- BOLD N/A
- Support Level
- PSNL $4.54
- BOLD N/A
- Resistance Level
- PSNL $5.35
- BOLD N/A
- Average True Range (ATR)
- PSNL 0.30
- BOLD 0.00
- MACD
- PSNL 0.05
- BOLD 0.00
- Stochastic Oscillator
- PSNL 84.71
- BOLD 0.00
About PSNL Personalis Inc.
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.
About BOLD Boundless Bio Inc. Common Stock
Boundless Bio Inc is a clinical-stage oncology company. It is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the significant unmet need in patients with oncogene amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in more than 14% of cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.